Eli Lilly’s investigational obesity pill largely helped patients maintain their weight loss after they switched from the potent injectable treatments Wegovy and Zepbound, the company said Thursday, results that could widen the appeal of the pill.
In a Phase 3 trial, one cohort of patients had an average starting weight of 113.5 kg. After over a year of taking Novo Nordisk’s Wegovy, their average weight dropped to 95 kg. Then, a year after switching to the pill, called orforglipron, patients’ average weight increased by just 0.9 kg.
A second cohort of patients had an average starting weight of 115.8 kg, which dropped to 90.9 kg after they took Lilly’s Zepbound. After switching to orforglipron, their average weight increased by 5 kg.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
